CHAMGAP

Topical 10% peppermint oil × Tension-type headache—equivalence to acetaminophen not established

Select a review item to see its details.
Required evidence, verification status and materials actually read
ItemAVerification statusBReading scopeCReview itemDCurrent findingsEWhy unverifiedFRequired materials and conditionsGFurther research
1 Partly verified Full text not readStored summary read N01 · Evidence conditionWhich acetaminophen comparison is being considered?Required
The selected original claim is analgesic efficacy equivalent to acetaminophen. The existing explanation records that the early trial was not designed to establish equivalence or noninferiority, separately from analgesia versus placebo.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Distinction between the existing equivalence question and analgesia versus placebo
Material needed: The original active-comparator design, denominators, effect, CI and prespecified margin are needed. This sheet is not counted as a new independent study. This records needed materials; no new research was executed.
2 Partly verified Full text not readStored summary read N02 · Evidence conditionDoes no difference establish equivalence or noninferiority?Required
The preserved account explains that no difference from acetaminophen did not establish equivalence. No new conclusion of equal or interchangeable treatments is made.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Nonsignificance in a superiority test versus prespecified equivalence or noninferiority criteria
Material needed: The prespecified clinical margin, effect of interest, test direction, relevant CI and analysis plan are needed. Nonsignificance is not converted into proof of equivalence. This records needed materials; no new research was executed.
3 Partly verified Full text not readStored summary read N03 · Evidence conditionAre the exact active-comparator effect, CI and P known?Required
The early result is a narrative of no difference from acetaminophen. Its exact effect, CI, P and test are absent from the summary; P<.01 concerns pain reduction versus placebo.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Estimate and precision of the direct comparison with acetaminophen
Material needed: Original active-comparator effect, CI, scale, time, denominators, testing and multiplicity materials are needed. The placebo P is not copied as the active-comparator P. This records needed materials; no new research was executed.
4 Partly verified Full text not readStored summary read N04 · Evidence conditionIs a signal versus placebo direct evidence of equivalence?Required
The early trial's pain reduction versus placebo, P<.01, is retained. This signal is not converted into a direct estimate of equivalence to acetaminophen or a prespecified equivalence trial.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Distinction between effects versus placebo and versus an active comparator
Material needed: The active-comparator effect, CI, original design and prespecified margin at the same time and analysis are needed. This records needed materials; no new research was executed.
5 Partly verified Full text not readStored summary read N05 · Evidence conditionAre 41 participants and 164 attacks the same denominator?Required
R01 is a repeated-attack crossover trial with 41 participants and 164 headache attacks. The 164 attacks are not labeled as participants or added as independent participants.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Participants, attacks, treatment periods and units of analysis
Material needed: Treatments and attacks per participant, allocation sequence, periods, endpoint-specific analysis denominators and repeated-data methods are needed. No new mean attack count is calculated. This records needed materials; no new research was executed.
6 Partly verified Full text not readStored summary read N06 · Evidence conditionAre crossover correlation, carryover and period effects verified?Required
The original design is a randomized double-blind repeated-attack crossover trial. Its label alone does not verify independence of attacks, washout, or handling of period and sequence effects.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Treatment sequence, washout, carryover and within-participant correlation
Material needed: Original allocation sequence, periods, washout, carryover tests, paired data, within-participant correlation and missing-data methods are needed. No independent parallel-group calculation is performed. This records needed materials; no new research was executed.
7 Unverified Full text not readStored summary read N07 · Evidence conditionAre acetaminophen dose, formulation and concurrent-care conditions known?Required
The preserved account records comparison with placebo or acetaminophen. The summary lacks exact acetaminophen dose, formulation, timing, concurrent care and rescue-medication conditions.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Arm-specific exposure conditions for active, topical and placebo comparisons
Material needed: Original arm-specific drugs, formulations, concurrent care, rescue medication, exposure and comparator conditions are needed. No new dose, use or administration guidance is created. This records needed materials; no new research was executed.
8 Partly verified Full text not readStored summary read N08 · Evidence conditionWhich 10% topical formulation was compared?Required
The parent account's topical 10% peppermint-oil and 90% ethanol solution is retained. Inhalation, oral enteric capsules and migraine involve different routes or populations; concentration is not converted into absorbed dose.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
The specific topical solution of 10% peppermint oil and 90% ethanol
Material needed: Original product, manufacture, composition, exposure, use records and comparator-vehicle details are needed. Formulations are distinguished by report, without new procedures or treatment guidance. This records needed materials; no new research was executed.
9 Partly verified Full text not readStored summary read N09 · Evidence conditionAre tension-type headache and migraine populations distinguished?Required
The original population has acute tension-type headache. The early 41 participants and 164 attacks do not replace detailed diagnosis or eligibility; the context excluding inhalation, enteric capsules and migraine is retained.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Eligibility and attack characteristics in acute tension-type headache
Material needed: Original diagnostic criteria, frequency, severity, baseline pain, exclusions, comorbidity and recruitment information are needed. Findings are not extended to other headaches or populations. This records needed materials; no new research was executed.
10 Partly verified Full text not readStored summary read N10 · Evidence conditionAre pain after 15 minutes and response at 120 minutes the same endpoint?Required
The early comparison concerns pain intensity from 15 minutes and an active comparator. The later first primary endpoint is VPRS response at 120 minutes, followed by VAS-SPID; these are not treated as the same scale, time or responder definition.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Timing and scales of early pain intensity and later VPRS response
Material needed: Each scale, response definition, baseline and follow-up, denominators, original analysis and prespecified hierarchy are needed. Times and scales are not converted or results merged. This records needed materials; no new research was executed.
11 Partly verified Full text not readStored summary read N11 · Evidence conditionWhat are the later trial's starting size and analysis denominators?Required
The later trial records 209 started, 189 in FAS and 94 versus 95. The 37/94 versus 28/95 comparison concerns response at 120 minutes; the starting count does not replace FAS denominators or event totals.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Distinction between 209 started, 189 in FAS and 94 versus 95
Material needed: Allocation, treatment and completion flow, FAS definition, exclusion and missingness reasons, and original arm-specific analysis populations are needed. No new count difference, response rate or effect is calculated. This records needed materials; no new research was executed.
12 Partly verified Full text not readStored summary read N12 · Evidence conditionIs failure of the later first primary endpoint's threshold retained?Required
The later response at 120 minutes, 37/94 versus 28/95, retains failure of the prespecified one-sided .025 threshold. A benefit direction is not converted into passing the threshold or an exactly 0 effect.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Prespecified one-sided Fisher .025 threshold and hierarchical gate
Material needed: Original registered results, prespecified plan, testing, denominators, direct effect and CI are needed. The original criterion is not replaced by a different two-sided .05 criterion. This records needed materials; no new research was executed.
13 Partly verified Full text not readStored summary read N13 · Evidence conditionWas two-sided Fisher P≈.101 calculated in this work?Required
The preserved result explicitly attributes two-sided Fisher P≈.101 to a historical Codex recalculation. The value and attribution are retained without presenting it as a current calculation or the original prespecified one-sided result.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Distinction between the historical Codex calculation from counts and original trial results
Material needed: Original results and analysis plan, and a separate record of the historical calculation, are needed. No statistical recalculation or new effect or CI is produced here. This records needed materials; no new research was executed.
14 Partly verified Full text not readStored summary read N14 · Evidence conditionIs VAS-SPID treated as confirmatory after the first primary endpoint failed?Required
The parent account treats the second VAS-SPID endpoint as exploratory after the first primary endpoint failed. The parent's secondary-result indicator is not converted into current confirmatory analgesia or successful equivalence.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Exploratory context of the hierarchically second endpoint
Material needed: The prespecified hierarchy, original second-endpoint result, CI, denominators, adjustment and testing procedures are needed. Unread values are not filled in. This records needed materials; no new research was executed.
15 Partly verified Full text not readStored summary read N15 · Evidence conditionIs the later placebo-controlled trial an active-comparator equivalence trial?Required
The later report is a registered placebo-controlled phase 4 trial. Its context as follow-up of a topical product is retained without turning it into a direct trial of equivalence to acetaminophen.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Distinction between the later placebo comparison and early acetaminophen comparison
Material needed: Prespecified active-comparator design, margin and CI directly addressing the selected question are needed. Results against a different comparator do not replace them. This records needed materials; no new research was executed.
16 Unverified Full text not readStored summary read N16 · Evidence conditionAre the prespecified equivalence margin and power known?Required
The existing explanation says that the early trial was not designed to establish equivalence or noninferiority. Original clinical margins, power and relevant analysis populations are absent; no difference alone does not certify substitutability.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Patient-important margin, sample-size plan, ITT and PP
Material needed: The basis for a prespecified clinical margin, sample-size plan, direct CI, ITT and PP definitions and sensitivity analyses are needed. No new margin or sample size is calculated. This records needed materials; no new research was executed.
17 Partly verified Full text not readStored summary read N17 · Evidence conditionDoes rapid pain relief establish sustained recovery or recurrence prevention?Required
The parent's scope is pain relief in acute tension-type headache. An early rapid signal is not converted into direct confirmation of sustained recovery, causal treatment, long-term prevention or replacement of acetaminophen.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Acute pain and response versus persistence, recurrence and rescue-medication outcomes
Material needed: Original definitions, denominators, effects and CIs for complete pain freedom, persistence, recurrence, rescue medication and patient-important outcomes are needed. This records needed materials; no new research was executed.
18 Partly verified Full text not readStored summary read N18 · Evidence conditionAre early positive findings and later failure both retained?Required
The parent account addresses both a small early signal and failure of the larger registered trial's first primary endpoint, prioritizing the later failure. Both results are retained and distinguished from directness for equivalence.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Early and later reports, and directness for the equivalence question
Material needed: Original material distinguishing products, populations, times, comparators, denominators, prespecified endpoints, effects and CIs in the two reports is needed. This records needed materials; no new research was executed.
19 Partly verified Full text not readStored summary read N19 · Evidence conditionAre funding, products, authorship and design or analysis involvement separated?Required
Specific early funding and manufacturer involvement are unverified; the later trial was sponsored by Cassella-med GmbH. The parent's I0 and weak-independence explanation are not converted into new category-specific conclusions of absence or causation.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Independence assessed by specific support and involvement categories
Material needed: Separate material on research funding, product provision, author affiliations and involvement in design, analysis and publication is needed. Sponsorship alone does not fill other categories. This records needed materials; no new research was executed.
20 Partly verified Full text not readStored summary read N20 · Evidence conditionAre denominators and collection methods for skin and eye harms known?Supplementary
The parent's safety wording concerns skin stinging, redness, eye injury and application boundaries for concentrated peppermint oil and ethanol. The summary lacks actual arm-specific harm counts, collection methods, denominators and exposure.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Topical harm events, exposure, routes and vulnerable groups
Material needed: Harm collection, events and affected people, severity, timing, exposure, arm-specific denominators and actual inclusion of children, eyes or mucosa are needed. No new use or treatment guidance is created. This records needed materials; no new research was executed.
21 Partly verified Full text not readStored summary read N21 · Evidence conditionAre shared reports and repeated attacks added as independent studies?Required
The early paper and later registered results are shared by the parent's two subquestions. The 41 participants, 164 attacks and 209/189 are not calculated as independent participant totals, and registered results are not certified as a separate paper.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Two reports, shared subquestions and registered-result versions
Material needed: Links among original trials, reports, sites, recruitment, participants and registration versions are needed. Unique trial, participant and independent-replication counts remain unverified. This records needed materials; no new research was executed.
22 Partly verified Full text not readStored summary read N22 · Evidence conditionAre registration IDs and posting dates distinguished from current reading?Required
The later NCT01770080, EudraCT 2011-004777-89 and results version 1 posting date 2025-05-22 are retained from the bibliography. The early pre-registration-era absence narrative is historical and does not represent current registration comparison.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
NCT01770080, EudraCT and posting of results version 1
Material needed: Actual original registration, plan, amendments and result-version materials are needed. The early record is not converted into a new registry-search conclusion, or a link into completed reading. This records needed materials; no new research was executed.
23 Partly verified Full text not readStored summary read N23 · Evidence conditionAre selected D and parent D28, Caution and axes distinguished?Required
The selected subquestion has D and lacks individual score, status and axes. Parent D28, Caution and axes remain parent context without filling a subclaim score.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Selected subclaim grade and absence of individual score, status and axes
Material needed: Content review of the subquestion and parent boundary remains incomplete. No new grade, score, clinical status or certification of independence is created. This records needed materials; no new research was executed.
24 Partly verified Full text not readStored summary read N24 · Evidence conditionAre stored-summary reading and external-original reading distinguished?Required
The preserved parent summary was read for production. Historical bibliographic claims of verification, cross-checking, full-text reading and calculation remain historical; external abstracts, full text, registration, protocols and SAPs are unread.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Materials actually read, separated by type
Material needed: External acquisition, reading and content review are separate events. A link does not establish original reading, accessibility or completed review. This records needed materials; no new research was executed.
25 Partly verified Full text not readStored summary read N25 · Evidence conditionHow far do representative values in the Korean and English accounts apply?Required
The parent's Korean and English accounts and representative values are preserved. Representative dose, population and endpoint summaries are not automatically applied as quantities, denominators or identical outcomes across every report, arm and endpoint.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Scope of language-specific accounts and representative formulation, population and endpoint
Material needed: Original material comparing report-specific populations, formulations, comparators, endpoints, times and denominators is needed. No current comparison with external English originals or correction review was performed. This records needed materials; no new research was executed.
26 Partly verified Full text not readStored summary read N26 · Evidence conditionAre the evidence date, empty correction history and production time distinguished?Required
The original evidence date is 2026-09-07, with an empty correction array and deliberation text. Production time does not become an evidence-verification date and no nonexistent correction is created.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Original evidence date versus correction and change events
Material needed: Material additions, criterion revisions, observation application and verdict changes must preserve the complete prior account and distinguish events, versions and reasons. This records needed materials; no new research was executed.
27 Partly verified Full text not readStored summary read N27 · Evidence conditionDo report or material-slot counts represent unique trials or quality scores?Required
Report links, stored summaries and external-material slots describe table structure. They are not acquired external papers, unique participants, original trials, independent replications or quality scores; shared material is not counted twice.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Table structure versus unique clinical units and actual reading
Material needed: Original trial, report and cohort links, and actual acquisition and reading records, are needed. Unique trial and participant counts remain unverified. This records needed materials; no new research was executed.
28 Partly verified Full text not readStored summary read N28 · Evidence conditionWhere should new material and corrections be linked?Required
Original material, existing conditions and observations are preserved. New material must link to relevant comparisons, denominators, endpoints, reports and subquestion boundaries; this production is not labeled as new retrieval or a revised verdict.
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Distinction between criterion revision, material updates and verdict changes
Material needed: After acquisition and content review, the complete prior account must be preserved and events, versions and reasons recorded. No new procedures, treatment guidance or calculations are created. This records needed materials; no new research was executed.
No items match your search or filter.

28 itemsWhat the statuses mean

Assessment scope

Stored-material review date
Not recorded
Original evidence cut-off
2026-09-07
Scope actually checked
Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean
This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population
The population has acute tension-type headache. Detailed diagnosis and eligibility in the early repeated-attack trial remain unverified; findings are not extended to migraine.
Ingredient, formulation and route
Topical application of 10% peppermint oil in ethanol to the forehead and temples. This is distinguished from inhalation and oral enteric capsules.
Dose
The early report's 10% oil and 90% ethanol conditions are retained. Exact acetaminophen dose, formulation, timing and concurrent-care conditions are absent from the summary.
Comparator
The selected question concerns the early active comparison with acetaminophen. The placebo signal and later placebo-controlled trial remain separate context.
Measured outcome
The question concerns active-comparator pain intensity and equivalence. No difference did not establish equivalence or noninferiority; direct effects, CIs and prespecified margins are unverified.
Duration
The early comparison concerns pain from 15 minutes. Later VPRS response at 120 minutes and VAS-SPID are not merged as the same scale or time.
Questions outside this scope
Converting nonsignificance into equivalence, noninferiority, an exactly zero effect or substitutability; Adding participants, repeated attacks, reports or shared subquestion sheets as independent participants or replications; Treating different formulations, populations, comparators, times, scales or acute and long-term questions as the same direct effect; Promoting historical verification, full-text reading or calculation narratives to current completion; Creating new effects, CIs, margins, sample sizes, grades, independence conclusions or use or treatment guidance

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Göbel H et al. 1996

PubMed

Material type
Randomized double-blind repeated-attack crossover trial; early active comparison
Materials actually read
Only the stored parent summary and bibliography were read. External abstracts, full text, registration, protocols and SAPs are unread.
Findings recorded in the stored summary
There were 41 participants and 164 headache attacks, with less pain than placebo, P<.01. No difference from acetaminophen did not establish equivalence; exact direct-comparison effects, CIs, P and prespecified margins are absent from the summary.
Record level
This is the stored summary of the early active comparison. No difference is distinguished from proof of equivalence or noninferiority; no current external paper reading, recalculation or reassessment was performed.
Study overlap and independent replication
The parent and its two subquestions share the early paper and later registered results. The preserved linkage is not counted as new independent trials or replications; unique trial and participant totals remain unverified.
Public availability, access and reading status by material
MaterialPublic availabilityAccess statusActually readNotes
Stored existing review summaryPreserved copy of the complete parent-verdict stored summaryStored summarySummary readThe early active comparison is linked from the stored bibliography and summary. Historical verification or full-text narratives and unverified funding or manufacturer involvement remain in internal originals and are not labeled as current external reading. Only stored-summary dates retain the original evidence date. Empty external-material dates remain empty and are not filled as actual reading or completed-review dates.
External abstractOriginal bibliographic link or needed material; external public availability/access status unverifiedUnread; access not attemptedNot readThe early active comparison is linked from the stored bibliography and summary. Historical verification or full-text narratives and unverified funding or manufacturer involvement remain in internal originals and are not labeled as current external reading. Only stored-summary dates retain the original evidence date. Empty external-material dates remain empty and are not filled as actual reading or completed-review dates.
External full textOriginal bibliographic link or needed material; external public availability/access status unverifiedUnread; access not attemptedNot readThe early active comparison is linked from the stored bibliography and summary. Historical verification or full-text narratives and unverified funding or manufacturer involvement remain in internal originals and are not labeled as current external reading. Only stored-summary dates retain the original evidence date. Empty external-material dates remain empty and are not filled as actual reading or completed-review dates.
Registration materialOriginal bibliographic link or needed material; external public availability/access status unverifiedUnread; access not attemptedNot readThe early active comparison is linked from the stored bibliography and summary. Historical verification or full-text narratives and unverified funding or manufacturer involvement remain in internal originals and are not labeled as current external reading. Only stored-summary dates retain the original evidence date. Empty external-material dates remain empty and are not filled as actual reading or completed-review dates.
Protocol and analysis planOriginal bibliographic link or needed material; external public availability/access status unverifiedUnread; access not attemptedNot readThe early active comparison is linked from the stored bibliography and summary. Historical verification or full-text narratives and unverified funding or manufacturer involvement remain in internal originals and are not labeled as current external reading. Only stored-summary dates retain the original evidence date. Empty external-material dates remain empty and are not filled as actual reading or completed-review dates.

R02 · Euminz tension-type headache phase 4 study · later registered results

Official source

Material type
Registered placebo-controlled phase 4 trial; separate context for active-comparator equivalence
Materials actually read
Only the stored parent summary and bibliography were read. External abstracts, full text, registration, protocols and SAPs are unread.
Findings recorded in the stored summary
There were 209 started, 189 in FAS and 94 versus 95. Response at 120 minutes, 37/94 versus 28/95, missed the prespecified one-sided .025 threshold; two-sided Fisher P≈.101 is a historical Codex recalculation. This is not a direct comparison of equivalence to acetaminophen.
Record level
This provides the later placebo comparison's first-primary-endpoint failure and hierarchical context. The second VAS-SPID endpoint is exploratory and is not converted into a current calculation or confirmation of selected equivalence.
Study overlap and independent replication
The parent and its two subquestions share the early paper and later registered results. The preserved linkage is not counted as new independent trials or replications; unique trial and participant totals remain unverified.
Public availability, access and reading status by material
MaterialPublic availabilityAccess statusActually readNotes
Stored existing review summaryPreserved copy of the complete parent-verdict stored summaryStored summarySummary readThe preserved bibliography's NCT01770080, EudraCT2011-004777-89 and Cassella-med GmbH sponsorship are retained. External verification of registered results, plans, amendments and company roles was not performed. Only stored-summary dates retain the original evidence date. Empty external-material dates remain empty and are not filled as actual reading or completed-review dates.
External abstractOriginal bibliographic link or needed material; external public availability/access status unverifiedUnread; access not attemptedNot readThe preserved bibliography's NCT01770080, EudraCT2011-004777-89 and Cassella-med GmbH sponsorship are retained. External verification of registered results, plans, amendments and company roles was not performed. Only stored-summary dates retain the original evidence date. Empty external-material dates remain empty and are not filled as actual reading or completed-review dates.
External full textOriginal bibliographic link or needed material; external public availability/access status unverifiedUnread; access not attemptedNot readThe preserved bibliography's NCT01770080, EudraCT2011-004777-89 and Cassella-med GmbH sponsorship are retained. External verification of registered results, plans, amendments and company roles was not performed. Only stored-summary dates retain the original evidence date. Empty external-material dates remain empty and are not filled as actual reading or completed-review dates.
Registration materialOriginal bibliographic link or needed material; external public availability/access status unverifiedUnread; access not attemptedNot readThe preserved bibliography's NCT01770080, EudraCT2011-004777-89 and Cassella-med GmbH sponsorship are retained. External verification of registered results, plans, amendments and company roles was not performed. Only stored-summary dates retain the original evidence date. Empty external-material dates remain empty and are not filled as actual reading or completed-review dates.
Protocol and analysis planOriginal bibliographic link or needed material; external public availability/access status unverifiedUnread; access not attemptedNot readThe preserved bibliography's NCT01770080, EudraCT2011-004777-89 and Cassella-med GmbH sponsorship are retained. External verification of registered results, plans, amendments and company roles was not performed. Only stored-summary dates retain the original evidence date. Empty external-material dates remain empty and are not filled as actual reading or completed-review dates.

Report counts versus independent study counts

The parent and its two subquestions share the early paper and later registered results. The preserved linkage is not counted as new independent trials or replications; unique trial and participant totals remain unverified.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which acetaminophen comparison is being considered?
Required materials and conditions
Distinction between the existing equivalence question and analgesia versus placebo
Conditions for verification
Original material on Distinction between the existing equivalence question and analgesia versus placebo must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Distinction between the existing equivalence question and analgesia versus placebo is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N02 · Does no difference establish equivalence or noninferiority?
Required materials and conditions
Nonsignificance in a superiority test versus prespecified equivalence or noninferiority criteria
Conditions for verification
Original material on Nonsignificance in a superiority test versus prespecified equivalence or noninferiority criteria must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Nonsignificance in a superiority test versus prespecified equivalence or noninferiority criteria is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N03 · Are the exact active-comparator effect, CI and P known?
Required materials and conditions
Estimate and precision of the direct comparison with acetaminophen
Conditions for verification
Original material on Estimate and precision of the direct comparison with acetaminophen must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Estimate and precision of the direct comparison with acetaminophen is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N04 · Is a signal versus placebo direct evidence of equivalence?
Required materials and conditions
Distinction between effects versus placebo and versus an active comparator
Conditions for verification
Original material on Distinction between effects versus placebo and versus an active comparator must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Distinction between effects versus placebo and versus an active comparator is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N05 · Are 41 participants and 164 attacks the same denominator?
Required materials and conditions
Participants, attacks, treatment periods and units of analysis
Conditions for verification
Original material on Participants, attacks, treatment periods and units of analysis must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Participants, attacks, treatment periods and units of analysis is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N06 · Are crossover correlation, carryover and period effects verified?
Required materials and conditions
Treatment sequence, washout, carryover and within-participant correlation
Conditions for verification
Original material on Treatment sequence, washout, carryover and within-participant correlation must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Treatment sequence, washout, carryover and within-participant correlation is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N07 · Are acetaminophen dose, formulation and concurrent-care conditions known?
Required materials and conditions
Arm-specific exposure conditions for active, topical and placebo comparisons
Conditions for verification
Original material on Arm-specific exposure conditions for active, topical and placebo comparisons must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Arm-specific exposure conditions for active, topical and placebo comparisons is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N08 · Which 10% topical formulation was compared?
Required materials and conditions
The specific topical solution of 10% peppermint oil and 90% ethanol
Conditions for verification
Original material on The specific topical solution of 10% peppermint oil and 90% ethanol must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on The specific topical solution of 10% peppermint oil and 90% ethanol is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N09 · Are tension-type headache and migraine populations distinguished?
Required materials and conditions
Eligibility and attack characteristics in acute tension-type headache
Conditions for verification
Original material on Eligibility and attack characteristics in acute tension-type headache must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Eligibility and attack characteristics in acute tension-type headache is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N10 · Are pain after 15 minutes and response at 120 minutes the same endpoint?
Required materials and conditions
Timing and scales of early pain intensity and later VPRS response
Conditions for verification
Original material on Timing and scales of early pain intensity and later VPRS response must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Timing and scales of early pain intensity and later VPRS response is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N11 · What are the later trial's starting size and analysis denominators?
Required materials and conditions
Distinction between 209 started, 189 in FAS and 94 versus 95
Conditions for verification
Original material on Distinction between 209 started, 189 in FAS and 94 versus 95 must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Distinction between 209 started, 189 in FAS and 94 versus 95 is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N12 · Is failure of the later first primary endpoint's threshold retained?
Required materials and conditions
Prespecified one-sided Fisher .025 threshold and hierarchical gate
Conditions for verification
Original material on Prespecified one-sided Fisher .025 threshold and hierarchical gate must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Prespecified one-sided Fisher .025 threshold and hierarchical gate is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N13 · Was two-sided Fisher P≈.101 calculated in this work?
Required materials and conditions
Distinction between the historical Codex calculation from counts and original trial results
Conditions for verification
Original material on Distinction between the historical Codex calculation from counts and original trial results must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Distinction between the historical Codex calculation from counts and original trial results is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N14 · Is VAS-SPID treated as confirmatory after the first primary endpoint failed?
Required materials and conditions
Exploratory context of the hierarchically second endpoint
Conditions for verification
Original material on Exploratory context of the hierarchically second endpoint must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Exploratory context of the hierarchically second endpoint is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N15 · Is the later placebo-controlled trial an active-comparator equivalence trial?
Required materials and conditions
Distinction between the later placebo comparison and early acetaminophen comparison
Conditions for verification
Original material on Distinction between the later placebo comparison and early acetaminophen comparison must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Distinction between the later placebo comparison and early acetaminophen comparison is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N16 · Are the prespecified equivalence margin and power known?
Required materials and conditions
Patient-important margin, sample-size plan, ITT and PP
Conditions for verification
Original material on Patient-important margin, sample-size plan, ITT and PP must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Patient-important margin, sample-size plan, ITT and PP is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N17 · Does rapid pain relief establish sustained recovery or recurrence prevention?
Required materials and conditions
Acute pain and response versus persistence, recurrence and rescue-medication outcomes
Conditions for verification
Original material on Acute pain and response versus persistence, recurrence and rescue-medication outcomes must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Acute pain and response versus persistence, recurrence and rescue-medication outcomes is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N18 · Are early positive findings and later failure both retained?
Required materials and conditions
Early and later reports, and directness for the equivalence question
Conditions for verification
Original material on Early and later reports, and directness for the equivalence question must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Early and later reports, and directness for the equivalence question is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N19 · Are funding, products, authorship and design or analysis involvement separated?
Required materials and conditions
Independence assessed by specific support and involvement categories
Conditions for verification
Original material on Independence assessed by specific support and involvement categories must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Independence assessed by specific support and involvement categories is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N20 · Are denominators and collection methods for skin and eye harms known?
Required materials and conditions
Topical harm events, exposure, routes and vulnerable groups
Conditions for verification
Original material on Topical harm events, exposure, routes and vulnerable groups must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Supplementary
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Topical harm events, exposure, routes and vulnerable groups is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N21 · Are shared reports and repeated attacks added as independent studies?
Required materials and conditions
Two reports, shared subquestions and registered-result versions
Conditions for verification
Original material on Two reports, shared subquestions and registered-result versions must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Two reports, shared subquestions and registered-result versions is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N22 · Are registration IDs and posting dates distinguished from current reading?
Required materials and conditions
NCT01770080, EudraCT and posting of results version 1
Conditions for verification
Original material on NCT01770080, EudraCT and posting of results version 1 must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on NCT01770080, EudraCT and posting of results version 1 is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N23 · Are selected D and parent D28, Caution and axes distinguished?
Required materials and conditions
Selected subclaim grade and absence of individual score, status and axes
Conditions for verification
Original material on Selected subclaim grade and absence of individual score, status and axes must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Selected subclaim grade and absence of individual score, status and axes is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N24 · Are stored-summary reading and external-original reading distinguished?
Required materials and conditions
Materials actually read, separated by type
Conditions for verification
Original material on Materials actually read, separated by type must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Materials actually read, separated by type is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N25 · How far do representative values in the Korean and English accounts apply?
Required materials and conditions
Scope of language-specific accounts and representative formulation, population and endpoint
Conditions for verification
Original material on Scope of language-specific accounts and representative formulation, population and endpoint must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Scope of language-specific accounts and representative formulation, population and endpoint is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N26 · Are the evidence date, empty correction history and production time distinguished?
Required materials and conditions
Original evidence date versus correction and change events
Conditions for verification
Original material on Original evidence date versus correction and change events must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Original evidence date versus correction and change events is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N27 · Do report or material-slot counts represent unique trials or quality scores?
Required materials and conditions
Table structure versus unique clinical units and actual reading
Conditions for verification
Original material on Table structure versus unique clinical units and actual reading must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Table structure versus unique clinical units and actual reading is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
N28 · Where should new material and corrections be linked?
Required materials and conditions
Distinction between criterion revision, material updates and verdict changes
Conditions for verification
Original material on Distinction between criterion revision, material updates and verdict changes must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Requirement and applicability
Required
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Why this condition is needed
Material on Distinction between criterion revision, material updates and verdict changes is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.
Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle
Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review
Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle
Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review
Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle
Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review
Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle
Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review
Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle
Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review
Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.
What the statuses mean
Partly verified
Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified
Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete
Review of existing content remains incomplete.
Met
This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
Not reported
Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible
This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable
Used only with an application exception and reason based on the question scope.
Conflicting data
This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions
This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-20 · Public page/material version 1.0

Public-facing views and materials were prepared from the existing 28 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-07) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which acetaminophen comparison is being considered?

Current findings
The selected original claim is analgesic efficacy equivalent to acetaminophen. The existing explanation records that the early trial was not designed to establish equivalence or noninferiority, separately from analgesia versus placebo.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
The original active-comparator design, denominators, effect, CI and prespecified margin are needed. This sheet is not counted as a new independent study.
Required materials and conditions
Distinction between the existing equivalence question and analgesia versus placebo
Materials to obtain first
The original active-comparator design, denominators, effect, CI and prespecified margin are needed. This sheet is not counted as a new independent study.
Further research
Material needed: The original active-comparator design, denominators, effect, CI and prespecified margin are needed. This sheet is not counted as a new independent study. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Distinction between the existing equivalence question and analgesia versus placebo must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Distinction between the existing equivalence question and analgesia versus placebo is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01

N02 · Does no difference establish equivalence or noninferiority?

Current findings
The preserved account explains that no difference from acetaminophen did not establish equivalence. No new conclusion of equal or interchangeable treatments is made.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
The prespecified clinical margin, effect of interest, test direction, relevant CI and analysis plan are needed. Nonsignificance is not converted into proof of equivalence.
Required materials and conditions
Nonsignificance in a superiority test versus prespecified equivalence or noninferiority criteria
Materials to obtain first
The prespecified clinical margin, effect of interest, test direction, relevant CI and analysis plan are needed. Nonsignificance is not converted into proof of equivalence.
Further research
Material needed: The prespecified clinical margin, effect of interest, test direction, relevant CI and analysis plan are needed. Nonsignificance is not converted into proof of equivalence. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Nonsignificance in a superiority test versus prespecified equivalence or noninferiority criteria must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Nonsignificance in a superiority test versus prespecified equivalence or noninferiority criteria is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01

N03 · Are the exact active-comparator effect, CI and P known?

Current findings
The early result is a narrative of no difference from acetaminophen. Its exact effect, CI, P and test are absent from the summary; P<.01 concerns pain reduction versus placebo.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original active-comparator effect, CI, scale, time, denominators, testing and multiplicity materials are needed. The placebo P is not copied as the active-comparator P.
Required materials and conditions
Estimate and precision of the direct comparison with acetaminophen
Materials to obtain first
Original active-comparator effect, CI, scale, time, denominators, testing and multiplicity materials are needed. The placebo P is not copied as the active-comparator P.
Further research
Material needed: Original active-comparator effect, CI, scale, time, denominators, testing and multiplicity materials are needed. The placebo P is not copied as the active-comparator P. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Estimate and precision of the direct comparison with acetaminophen must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Estimate and precision of the direct comparison with acetaminophen is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01

N04 · Is a signal versus placebo direct evidence of equivalence?

Current findings
The early trial's pain reduction versus placebo, P<.01, is retained. This signal is not converted into a direct estimate of equivalence to acetaminophen or a prespecified equivalence trial.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
The active-comparator effect, CI, original design and prespecified margin at the same time and analysis are needed.
Required materials and conditions
Distinction between effects versus placebo and versus an active comparator
Materials to obtain first
The active-comparator effect, CI, original design and prespecified margin at the same time and analysis are needed.
Further research
Material needed: The active-comparator effect, CI, original design and prespecified margin at the same time and analysis are needed. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Distinction between effects versus placebo and versus an active comparator must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Distinction between effects versus placebo and versus an active comparator is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01

N05 · Are 41 participants and 164 attacks the same denominator?

Current findings
R01 is a repeated-attack crossover trial with 41 participants and 164 headache attacks. The 164 attacks are not labeled as participants or added as independent participants.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Treatments and attacks per participant, allocation sequence, periods, endpoint-specific analysis denominators and repeated-data methods are needed. No new mean attack count is calculated.
Required materials and conditions
Participants, attacks, treatment periods and units of analysis
Materials to obtain first
Treatments and attacks per participant, allocation sequence, periods, endpoint-specific analysis denominators and repeated-data methods are needed. No new mean attack count is calculated.
Further research
Material needed: Treatments and attacks per participant, allocation sequence, periods, endpoint-specific analysis denominators and repeated-data methods are needed. No new mean attack count is calculated. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Participants, attacks, treatment periods and units of analysis must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Participants, attacks, treatment periods and units of analysis is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01

N06 · Are crossover correlation, carryover and period effects verified?

Current findings
The original design is a randomized double-blind repeated-attack crossover trial. Its label alone does not verify independence of attacks, washout, or handling of period and sequence effects.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original allocation sequence, periods, washout, carryover tests, paired data, within-participant correlation and missing-data methods are needed. No independent parallel-group calculation is performed.
Required materials and conditions
Treatment sequence, washout, carryover and within-participant correlation
Materials to obtain first
Original allocation sequence, periods, washout, carryover tests, paired data, within-participant correlation and missing-data methods are needed. No independent parallel-group calculation is performed.
Further research
Material needed: Original allocation sequence, periods, washout, carryover tests, paired data, within-participant correlation and missing-data methods are needed. No independent parallel-group calculation is performed. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Treatment sequence, washout, carryover and within-participant correlation must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Treatment sequence, washout, carryover and within-participant correlation is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01

N07 · Are acetaminophen dose, formulation and concurrent-care conditions known?

Current findings
The preserved account records comparison with placebo or acetaminophen. The summary lacks exact acetaminophen dose, formulation, timing, concurrent care and rescue-medication conditions.
Verification status
Unverified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original arm-specific drugs, formulations, concurrent care, rescue medication, exposure and comparator conditions are needed. No new dose, use or administration guidance is created.
Required materials and conditions
Arm-specific exposure conditions for active, topical and placebo comparisons
Materials to obtain first
Original arm-specific drugs, formulations, concurrent care, rescue medication, exposure and comparator conditions are needed. No new dose, use or administration guidance is created.
Further research
Material needed: Original arm-specific drugs, formulations, concurrent care, rescue medication, exposure and comparator conditions are needed. No new dose, use or administration guidance is created. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Arm-specific exposure conditions for active, topical and placebo comparisons must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Arm-specific exposure conditions for active, topical and placebo comparisons is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01

N08 · Which 10% topical formulation was compared?

Current findings
The parent account's topical 10% peppermint-oil and 90% ethanol solution is retained. Inhalation, oral enteric capsules and migraine involve different routes or populations; concentration is not converted into absorbed dose.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original product, manufacture, composition, exposure, use records and comparator-vehicle details are needed. Formulations are distinguished by report, without new procedures or treatment guidance.
Required materials and conditions
The specific topical solution of 10% peppermint oil and 90% ethanol
Materials to obtain first
Original product, manufacture, composition, exposure, use records and comparator-vehicle details are needed. Formulations are distinguished by report, without new procedures or treatment guidance.
Further research
Material needed: Original product, manufacture, composition, exposure, use records and comparator-vehicle details are needed. Formulations are distinguished by report, without new procedures or treatment guidance. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on The specific topical solution of 10% peppermint oil and 90% ethanol must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on The specific topical solution of 10% peppermint oil and 90% ethanol is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N09 · Are tension-type headache and migraine populations distinguished?

Current findings
The original population has acute tension-type headache. The early 41 participants and 164 attacks do not replace detailed diagnosis or eligibility; the context excluding inhalation, enteric capsules and migraine is retained.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original diagnostic criteria, frequency, severity, baseline pain, exclusions, comorbidity and recruitment information are needed. Findings are not extended to other headaches or populations.
Required materials and conditions
Eligibility and attack characteristics in acute tension-type headache
Materials to obtain first
Original diagnostic criteria, frequency, severity, baseline pain, exclusions, comorbidity and recruitment information are needed. Findings are not extended to other headaches or populations.
Further research
Material needed: Original diagnostic criteria, frequency, severity, baseline pain, exclusions, comorbidity and recruitment information are needed. Findings are not extended to other headaches or populations. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Eligibility and attack characteristics in acute tension-type headache must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Eligibility and attack characteristics in acute tension-type headache is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N10 · Are pain after 15 minutes and response at 120 minutes the same endpoint?

Current findings
The early comparison concerns pain intensity from 15 minutes and an active comparator. The later first primary endpoint is VPRS response at 120 minutes, followed by VAS-SPID; these are not treated as the same scale, time or responder definition.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Each scale, response definition, baseline and follow-up, denominators, original analysis and prespecified hierarchy are needed. Times and scales are not converted or results merged.
Required materials and conditions
Timing and scales of early pain intensity and later VPRS response
Materials to obtain first
Each scale, response definition, baseline and follow-up, denominators, original analysis and prespecified hierarchy are needed. Times and scales are not converted or results merged.
Further research
Material needed: Each scale, response definition, baseline and follow-up, denominators, original analysis and prespecified hierarchy are needed. Times and scales are not converted or results merged. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Timing and scales of early pain intensity and later VPRS response must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Timing and scales of early pain intensity and later VPRS response is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N11 · What are the later trial's starting size and analysis denominators?

Current findings
The later trial records 209 started, 189 in FAS and 94 versus 95. The 37/94 versus 28/95 comparison concerns response at 120 minutes; the starting count does not replace FAS denominators or event totals.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Allocation, treatment and completion flow, FAS definition, exclusion and missingness reasons, and original arm-specific analysis populations are needed. No new count difference, response rate or effect is calculated.
Required materials and conditions
Distinction between 209 started, 189 in FAS and 94 versus 95
Materials to obtain first
Allocation, treatment and completion flow, FAS definition, exclusion and missingness reasons, and original arm-specific analysis populations are needed. No new count difference, response rate or effect is calculated.
Further research
Material needed: Allocation, treatment and completion flow, FAS definition, exclusion and missingness reasons, and original arm-specific analysis populations are needed. No new count difference, response rate or effect is calculated. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Distinction between 209 started, 189 in FAS and 94 versus 95 must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Distinction between 209 started, 189 in FAS and 94 versus 95 is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R02

N12 · Is failure of the later first primary endpoint's threshold retained?

Current findings
The later response at 120 minutes, 37/94 versus 28/95, retains failure of the prespecified one-sided .025 threshold. A benefit direction is not converted into passing the threshold or an exactly 0 effect.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original registered results, prespecified plan, testing, denominators, direct effect and CI are needed. The original criterion is not replaced by a different two-sided .05 criterion.
Required materials and conditions
Prespecified one-sided Fisher .025 threshold and hierarchical gate
Materials to obtain first
Original registered results, prespecified plan, testing, denominators, direct effect and CI are needed. The original criterion is not replaced by a different two-sided .05 criterion.
Further research
Material needed: Original registered results, prespecified plan, testing, denominators, direct effect and CI are needed. The original criterion is not replaced by a different two-sided .05 criterion. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Prespecified one-sided Fisher .025 threshold and hierarchical gate must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Prespecified one-sided Fisher .025 threshold and hierarchical gate is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R02

N13 · Was two-sided Fisher P≈.101 calculated in this work?

Current findings
The preserved result explicitly attributes two-sided Fisher P≈.101 to a historical Codex recalculation. The value and attribution are retained without presenting it as a current calculation or the original prespecified one-sided result.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original results and analysis plan, and a separate record of the historical calculation, are needed. No statistical recalculation or new effect or CI is produced here.
Required materials and conditions
Distinction between the historical Codex calculation from counts and original trial results
Materials to obtain first
Original results and analysis plan, and a separate record of the historical calculation, are needed. No statistical recalculation or new effect or CI is produced here.
Further research
Material needed: Original results and analysis plan, and a separate record of the historical calculation, are needed. No statistical recalculation or new effect or CI is produced here. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Distinction between the historical Codex calculation from counts and original trial results must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Distinction between the historical Codex calculation from counts and original trial results is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R02

N14 · Is VAS-SPID treated as confirmatory after the first primary endpoint failed?

Current findings
The parent account treats the second VAS-SPID endpoint as exploratory after the first primary endpoint failed. The parent's secondary-result indicator is not converted into current confirmatory analgesia or successful equivalence.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
The prespecified hierarchy, original second-endpoint result, CI, denominators, adjustment and testing procedures are needed. Unread values are not filled in.
Required materials and conditions
Exploratory context of the hierarchically second endpoint
Materials to obtain first
The prespecified hierarchy, original second-endpoint result, CI, denominators, adjustment and testing procedures are needed. Unread values are not filled in.
Further research
Material needed: The prespecified hierarchy, original second-endpoint result, CI, denominators, adjustment and testing procedures are needed. Unread values are not filled in. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Exploratory context of the hierarchically second endpoint must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Exploratory context of the hierarchically second endpoint is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R02

N15 · Is the later placebo-controlled trial an active-comparator equivalence trial?

Current findings
The later report is a registered placebo-controlled phase 4 trial. Its context as follow-up of a topical product is retained without turning it into a direct trial of equivalence to acetaminophen.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Prespecified active-comparator design, margin and CI directly addressing the selected question are needed. Results against a different comparator do not replace them.
Required materials and conditions
Distinction between the later placebo comparison and early acetaminophen comparison
Materials to obtain first
Prespecified active-comparator design, margin and CI directly addressing the selected question are needed. Results against a different comparator do not replace them.
Further research
Material needed: Prespecified active-comparator design, margin and CI directly addressing the selected question are needed. Results against a different comparator do not replace them. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Distinction between the later placebo comparison and early acetaminophen comparison must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Distinction between the later placebo comparison and early acetaminophen comparison is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N16 · Are the prespecified equivalence margin and power known?

Current findings
The existing explanation says that the early trial was not designed to establish equivalence or noninferiority. Original clinical margins, power and relevant analysis populations are absent; no difference alone does not certify substitutability.
Verification status
Unverified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
The basis for a prespecified clinical margin, sample-size plan, direct CI, ITT and PP definitions and sensitivity analyses are needed. No new margin or sample size is calculated.
Required materials and conditions
Patient-important margin, sample-size plan, ITT and PP
Materials to obtain first
The basis for a prespecified clinical margin, sample-size plan, direct CI, ITT and PP definitions and sensitivity analyses are needed. No new margin or sample size is calculated.
Further research
Material needed: The basis for a prespecified clinical margin, sample-size plan, direct CI, ITT and PP definitions and sensitivity analyses are needed. No new margin or sample size is calculated. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Patient-important margin, sample-size plan, ITT and PP must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Patient-important margin, sample-size plan, ITT and PP is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01

N17 · Does rapid pain relief establish sustained recovery or recurrence prevention?

Current findings
The parent's scope is pain relief in acute tension-type headache. An early rapid signal is not converted into direct confirmation of sustained recovery, causal treatment, long-term prevention or replacement of acetaminophen.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original definitions, denominators, effects and CIs for complete pain freedom, persistence, recurrence, rescue medication and patient-important outcomes are needed.
Required materials and conditions
Acute pain and response versus persistence, recurrence and rescue-medication outcomes
Materials to obtain first
Original definitions, denominators, effects and CIs for complete pain freedom, persistence, recurrence, rescue medication and patient-important outcomes are needed.
Further research
Material needed: Original definitions, denominators, effects and CIs for complete pain freedom, persistence, recurrence, rescue medication and patient-important outcomes are needed. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Acute pain and response versus persistence, recurrence and rescue-medication outcomes must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Acute pain and response versus persistence, recurrence and rescue-medication outcomes is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N18 · Are early positive findings and later failure both retained?

Current findings
The parent account addresses both a small early signal and failure of the larger registered trial's first primary endpoint, prioritizing the later failure. Both results are retained and distinguished from directness for equivalence.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original material distinguishing products, populations, times, comparators, denominators, prespecified endpoints, effects and CIs in the two reports is needed.
Required materials and conditions
Early and later reports, and directness for the equivalence question
Materials to obtain first
Original material distinguishing products, populations, times, comparators, denominators, prespecified endpoints, effects and CIs in the two reports is needed.
Further research
Material needed: Original material distinguishing products, populations, times, comparators, denominators, prespecified endpoints, effects and CIs in the two reports is needed. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Early and later reports, and directness for the equivalence question must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Early and later reports, and directness for the equivalence question is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N19 · Are funding, products, authorship and design or analysis involvement separated?

Current findings
Specific early funding and manufacturer involvement are unverified; the later trial was sponsored by Cassella-med GmbH. The parent's I0 and weak-independence explanation are not converted into new category-specific conclusions of absence or causation.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Separate material on research funding, product provision, author affiliations and involvement in design, analysis and publication is needed. Sponsorship alone does not fill other categories.
Required materials and conditions
Independence assessed by specific support and involvement categories
Materials to obtain first
Separate material on research funding, product provision, author affiliations and involvement in design, analysis and publication is needed. Sponsorship alone does not fill other categories.
Further research
Material needed: Separate material on research funding, product provision, author affiliations and involvement in design, analysis and publication is needed. Sponsorship alone does not fill other categories. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Independence assessed by specific support and involvement categories must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Independence assessed by specific support and involvement categories is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N20 · Are denominators and collection methods for skin and eye harms known?

Current findings
The parent's safety wording concerns skin stinging, redness, eye injury and application boundaries for concentrated peppermint oil and ethanol. The summary lacks actual arm-specific harm counts, collection methods, denominators and exposure.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Harm collection, events and affected people, severity, timing, exposure, arm-specific denominators and actual inclusion of children, eyes or mucosa are needed. No new use or treatment guidance is created.
Required materials and conditions
Topical harm events, exposure, routes and vulnerable groups
Materials to obtain first
Harm collection, events and affected people, severity, timing, exposure, arm-specific denominators and actual inclusion of children, eyes or mucosa are needed. No new use or treatment guidance is created.
Further research
Material needed: Harm collection, events and affected people, severity, timing, exposure, arm-specific denominators and actual inclusion of children, eyes or mucosa are needed. No new use or treatment guidance is created. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Topical harm events, exposure, routes and vulnerable groups must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Topical harm events, exposure, routes and vulnerable groups is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N21 · Are shared reports and repeated attacks added as independent studies?

Current findings
The early paper and later registered results are shared by the parent's two subquestions. The 41 participants, 164 attacks and 209/189 are not calculated as independent participant totals, and registered results are not certified as a separate paper.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Links among original trials, reports, sites, recruitment, participants and registration versions are needed. Unique trial, participant and independent-replication counts remain unverified.
Required materials and conditions
Two reports, shared subquestions and registered-result versions
Materials to obtain first
Links among original trials, reports, sites, recruitment, participants and registration versions are needed. Unique trial, participant and independent-replication counts remain unverified.
Further research
Material needed: Links among original trials, reports, sites, recruitment, participants and registration versions are needed. Unique trial, participant and independent-replication counts remain unverified. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Two reports, shared subquestions and registered-result versions must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Two reports, shared subquestions and registered-result versions is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N22 · Are registration IDs and posting dates distinguished from current reading?

Current findings
The later NCT01770080, EudraCT 2011-004777-89 and results version 1 posting date 2025-05-22 are retained from the bibliography. The early pre-registration-era absence narrative is historical and does not represent current registration comparison.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Actual original registration, plan, amendments and result-version materials are needed. The early record is not converted into a new registry-search conclusion, or a link into completed reading.
Required materials and conditions
NCT01770080, EudraCT and posting of results version 1
Materials to obtain first
Actual original registration, plan, amendments and result-version materials are needed. The early record is not converted into a new registry-search conclusion, or a link into completed reading.
Further research
Material needed: Actual original registration, plan, amendments and result-version materials are needed. The early record is not converted into a new registry-search conclusion, or a link into completed reading. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on NCT01770080, EudraCT and posting of results version 1 must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on NCT01770080, EudraCT and posting of results version 1 is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N23 · Are selected D and parent D28, Caution and axes distinguished?

Current findings
The selected subquestion has D and lacks individual score, status and axes. Parent D28, Caution and axes remain parent context without filling a subclaim score.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Content review of the subquestion and parent boundary remains incomplete. No new grade, score, clinical status or certification of independence is created.
Required materials and conditions
Selected subclaim grade and absence of individual score, status and axes
Materials to obtain first
Content review of the subquestion and parent boundary remains incomplete. No new grade, score, clinical status or certification of independence is created.
Further research
Material needed: Content review of the subquestion and parent boundary remains incomplete. No new grade, score, clinical status or certification of independence is created. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Selected subclaim grade and absence of individual score, status and axes must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Selected subclaim grade and absence of individual score, status and axes is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N24 · Are stored-summary reading and external-original reading distinguished?

Current findings
The preserved parent summary was read for production. Historical bibliographic claims of verification, cross-checking, full-text reading and calculation remain historical; external abstracts, full text, registration, protocols and SAPs are unread.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
External acquisition, reading and content review are separate events. A link does not establish original reading, accessibility or completed review.
Required materials and conditions
Materials actually read, separated by type
Materials to obtain first
External acquisition, reading and content review are separate events. A link does not establish original reading, accessibility or completed review.
Further research
Material needed: External acquisition, reading and content review are separate events. A link does not establish original reading, accessibility or completed review. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Materials actually read, separated by type must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Materials actually read, separated by type is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N25 · How far do representative values in the Korean and English accounts apply?

Current findings
The parent's Korean and English accounts and representative values are preserved. Representative dose, population and endpoint summaries are not automatically applied as quantities, denominators or identical outcomes across every report, arm and endpoint.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original material comparing report-specific populations, formulations, comparators, endpoints, times and denominators is needed. No current comparison with external English originals or correction review was performed.
Required materials and conditions
Scope of language-specific accounts and representative formulation, population and endpoint
Materials to obtain first
Original material comparing report-specific populations, formulations, comparators, endpoints, times and denominators is needed. No current comparison with external English originals or correction review was performed.
Further research
Material needed: Original material comparing report-specific populations, formulations, comparators, endpoints, times and denominators is needed. No current comparison with external English originals or correction review was performed. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Scope of language-specific accounts and representative formulation, population and endpoint must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Scope of language-specific accounts and representative formulation, population and endpoint is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N26 · Are the evidence date, empty correction history and production time distinguished?

Current findings
The original evidence date is 2026-09-07, with an empty correction array and deliberation text. Production time does not become an evidence-verification date and no nonexistent correction is created.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Material additions, criterion revisions, observation application and verdict changes must preserve the complete prior account and distinguish events, versions and reasons.
Required materials and conditions
Original evidence date versus correction and change events
Materials to obtain first
Material additions, criterion revisions, observation application and verdict changes must preserve the complete prior account and distinguish events, versions and reasons.
Further research
Material needed: Material additions, criterion revisions, observation application and verdict changes must preserve the complete prior account and distinguish events, versions and reasons. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Original evidence date versus correction and change events must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Original evidence date versus correction and change events is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N27 · Do report or material-slot counts represent unique trials or quality scores?

Current findings
Report links, stored summaries and external-material slots describe table structure. They are not acquired external papers, unique participants, original trials, independent replications or quality scores; shared material is not counted twice.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
Original trial, report and cohort links, and actual acquisition and reading records, are needed. Unique trial and participant counts remain unverified.
Required materials and conditions
Table structure versus unique clinical units and actual reading
Materials to obtain first
Original trial, report and cohort links, and actual acquisition and reading records, are needed. Unique trial and participant counts remain unverified.
Further research
Material needed: Original trial, report and cohort links, and actual acquisition and reading records, are needed. Unique trial and participant counts remain unverified. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Table structure versus unique clinical units and actual reading must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Table structure versus unique clinical units and actual reading is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02

N28 · Where should new material and corrections be linked?

Current findings
Original material, existing conditions and observations are preserved. New material must link to relevant comparisons, denominators, endpoints, reports and subquestion boundaries; this production is not labeled as new retrieval or a revised verdict.
Verification status
Partly verified
Materials actually read
Stored parent summary and bibliography read; external abstracts, full text, registered results, registration, protocols and SAPs unread
Why unverified
Information was transferred from the stored summary with the selected question distinguished from parent context. Detailed originals and content review remain incomplete; this does not establish clinical certification or review approval.
Reason for missing information
After acquisition and content review, the complete prior account must be preserved and events, versions and reasons recorded. No new procedures, treatment guidance or calculations are created.
Required materials and conditions
Distinction between criterion revision, material updates and verdict changes
Materials to obtain first
After acquisition and content review, the complete prior account must be preserved and events, versions and reasons recorded. No new procedures, treatment guidance or calculations are created.
Further research
Material needed: After acquisition and content review, the complete prior account must be preserved and events, versions and reasons recorded. No new procedures, treatment guidance or calculations are created. This records needed materials; no new research was executed.
Remaining uncertainty
Exact active-comparator effects, CIs, testing, denominators, prespecified margins, power, dose, formulation, concurrent care, missingness and harms remain unverified. Placebo signals, later first-primary-endpoint failure and historical calculation are distinguished; no difference is not converted into equivalence, noninferiority, an exactly zero effect or substitutability.
Conditions for verification
Original material on Distinction between criterion revision, material updates and verdict changes must link to the report-specific population, formulation, comparator, time, endpoint, denominators and prespecified analysis, distinguishing direct comparison, parent context, historical calculation and unread external materials.
Why this condition is needed
Material on Distinction between criterion revision, material updates and verdict changes is needed to connect the selected active-comparator question with formulation, population, comparator, timing, scales, denominators, precision and harms.
Application exceptions
Original details absent from the summary remain unverified. Selected D and the absence of individual score, status and axes are retained without inheriting parent D28. No new effect, CI, margin, sample size, grade, equivalence, safety or independence certification, or use or treatment guidance is created.
Referenced methods
Preserved principles distinguishing questions, comparators, reports and trials, endpoints, denominators and harms informed production.

Related sources R01 R02